A Phase 4 interventional study of MK0663, etoricoxib / Duration of Treatment: 4 weeks and Comparator: diclofenac / Duration of Treatment: 4 weeks in Chronic Low Back Pain, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-15.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy of MK0663 for the treatment of chronic low back pain and to investigate the overall safety and tolerability over four weeks of treatment.
2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.
This study's enrollment of 401 is above the median of 60 across 2,366 interventional studies indexed under Low Back Pain.
Browse Low Back Pain studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Lower back pain intensity
Safety and tolerability
Disability questionnaire
Patient global assessment of response to therapy
No study locations are listed for this record.
The record gives a start of Jun 2004, a primary completion of Mar 2005 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.